Skip to main content
DiaSorin

DiaSorin

Educational videos

Pursuant to the New Guidelines of the Ministry of Health dated 20/12/2017 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professional operators

A talk with Christopher Labdon
25/07/2019
A day in the lab
25/07/2019
H. Pylori Ag concepts
27/02/2018
Is primary aldosteronism still largely unrecognized?
27/02/2018
Case report of Calprotectin
20/02/2018
Clinical utility and diagnostic approach for FGF 23
20/02/2018
Clinical utility of Stool testing, focus on Calprotectin
20/02/2018
Clinical utility, current intended use and future possible applications of 1,25
20/02/2018
FGF 23 Lectio Magistralis by Prof. Myles Wolf
23/02/2017
Toxoplasma gondii, cytomegalovirus and Treponema pallidum infection in pregnancy: what's new ?"
04/07/2016
How efficient and automated can be Serology and Stool testing
04/08/2015
1,25 Dihydroxyvitamin D, a revolutionary assay format
24/01/2015
DiaSorin scientific contribution at IFCC WorldLab 2014: Use of the Aldosterone and Renin Ratio for earlier diagnosis of Primary Aldosteronism
01/07/2014
DiaSorin scientific contribution at IFCC WorldLab 2014: Testing Vitamin D beyond 25-OH
24/06/2014
DiaSorin scientific contribution to EuroMedLab 2013: discriminating different forms of hypertension
30/05/2013

Educational

  • Home
  • Clinical Areas
  • Educational Videos
  • Articles & Posters
  • Webinars
  • DiaSorin Symposia

Contacts

Contacts

  • Diasorin Group
  • Diasorin Molecular
  • Legal Notices
  • Privacy Policy
  • Modern Slavery Act Statement

DiaSorin S.p.A. - Share Capital € 55.948.257 R.E.A. 180729
Fiscal Code and Subscription to Vercelli Companies Register no 13144290155

  • English
  • Italiano
Scroll down
▼
close
Android Iphone